Literature DB >> 18231697

Duloxetine 1 year on: the long-term outcome of a cohort of women prescribed duloxetine.

Maria Vella1, Jonathan Duckett, Maya Basu.   

Abstract

This aim of this study was to determine the long-term persistence with duloxetine in a cohort of women treated for stress incontinence and any alternative treatments undertaken. Two hundred twenty-eight women prescribed duloxetine were initially reviewed after 4 weeks of treatment. Women continuing therapy were reassessed at 4 and 6 months and 1 year with a review of all treatments after 1 year. At each visit, they were asked about persistence with duloxetine, reasons for discontinuation and any alternative treatments. Seventy-one (31%) women continued beyond 4 weeks of treatment, and twenty-six (12%) were taking duloxetine 4 months later, 23 (10%) at 6 months and 21 (9%) at 1 year. One year later, 187 (82%) women had a tension-free vaginal tape operation (TVT). The majority of women discontinued because of side effects (56%) or lack of efficacy (33%). Few women persevere with duloxetine beyond 4 months. One year later, the majority of women had a TVT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18231697     DOI: 10.1007/s00192-008-0564-4

Source DB:  PubMed          Journal:  Int Urogynecol J Pelvic Floor Dysfunct


  12 in total

1.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Am J Obstet Gynecol       Date:  2002-07       Impact factor: 8.661

2.  Tolerability and efficacy of duloxetine in a nontrial situation.

Authors:  J R A Duckett; M Vella; G Kavalakuntla; M Basu
Journal:  BJOG       Date:  2007-03-13       Impact factor: 6.531

3.  Outcome measures in urogynaecology: the clinicians' perspective.

Authors:  Dudley Robinson; Kate Anders; Linda Cardozo; John Bidmead
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-06-28

4.  A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance.

Authors:  C J Kelleher; L D Cardozo; V Khullar; S Salvatore
Journal:  Br J Obstet Gynaecol       Date:  1997-09

5.  Pharmacological treatment of women awaiting surgery for stress urinary incontinence.

Authors:  Linda Cardozo; Harold P Drutz; Simin K Baygani; Richard C Bump
Journal:  Obstet Gynecol       Date:  2004-09       Impact factor: 7.661

6.  Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence.

Authors:  Roger R Dmochowski; John R Miklos; Peggy A Norton; Norman R Zinner; Ilker Yalcin; Richard C Bump
Journal:  J Urol       Date:  2003-10       Impact factor: 7.450

7.  Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial.

Authors:  R J Millard; K Moore; R Rencken; I Yalcin; R C Bump
Journal:  BJU Int       Date:  2004-02       Impact factor: 5.588

8.  Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence.

Authors:  Philip van Kerrebroeck; Paul Abrams; Rainer Lange; Mark Slack; Jean-Jacques Wyndaele; Ilker Yalcin; Richard C Bump
Journal:  BJOG       Date:  2004-03       Impact factor: 6.531

9.  Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence.

Authors:  Alfred E Bent; Angelo E Gousse; Susan L Hendrix; Carl G Klutke; Ash K Monga; Chui K Yuen; David Muram; Ilker Yalcin; Richard C Bump
Journal:  Neurourol Urodyn       Date:  2008       Impact factor: 2.696

10.  A prospective multicenter randomized trial of tension-free vaginal tape and colposuspension for primary urodynamic stress incontinence: two-year follow-up.

Authors:  Karen L Ward; Paul Hilton
Journal:  Am J Obstet Gynecol       Date:  2004-02       Impact factor: 8.661

View more
  9 in total

1.  Analytic model comparing the cost utility of TVT versus duloxetine in women with urinary stress incontinence.

Authors:  Paul Jacklin; Jonathan Duckett; Arasee Renganathan
Journal:  Int Urogynecol J       Date:  2010-03-27       Impact factor: 2.894

2.  Management of urinary incontinence.

Authors:  George A Demaagd; Timothy C Davenport
Journal:  P T       Date:  2012-06

3.  Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports.

Authors:  Emma Maund; Louise Schow Guski; Peter C Gøtzsche
Journal:  CMAJ       Date:  2016-11-14       Impact factor: 8.262

Review 4.  Mixed urinary incontinence: international urogynecological association research and development committee opinion.

Authors:  Dorothy Kammerer-Doak; Diaa E E Rizk; Olanrewaju Sorinola; Wael Agur; Sharif Ismail; Tony Bazi
Journal:  Int Urogynecol J       Date:  2014-08-05       Impact factor: 2.894

5.  [Stress incontinence in elderly women].

Authors:  H Loertzer; P Schneider
Journal:  Urologe A       Date:  2013-06       Impact factor: 0.639

6.  Nonsurgical outpatient therapies for the management of female stress urinary incontinence: long-term effectiveness and durability.

Authors:  G Willy Davila
Journal:  Adv Urol       Date:  2011-06-23

7.  Use of symptom-relieving drugs before and after surgery for urinary incontinence in women: a cohort study.

Authors:  Rikke Guldberg; Søren Brostrøm; Ulrik Schiøler Kesmodel; Linda Kærlev; Jesper Kjær Hansen; Jesper Hallas; Bente Mertz Nørgård
Journal:  BMJ Open       Date:  2013-11-19       Impact factor: 2.692

8.  Clinical study of effectiveness and safety of CELcomplex® containing Cucurbita Pepo Seed extract and Flax and Casuarina on stress urinary incontinence in women.

Authors:  Andrea Gažová; Simona Valášková; Viera Žufková; Ana M Castejon; Ján Kyselovič
Journal:  J Tradit Complement Med       Date:  2018-05-03

Review 9.  Update on duloxetine for the management of stress urinary incontinence.

Authors:  Maya Basu; Jonathan R A Duckett
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.